Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation

Abstract

Non-valvular atrial fibrillation is becoming more common in Australia and globally. The direct oral anticoagulants apixaban, dabigatran and rivaroxaban offer an improved safety profile over warfarin. Patient preferences are important and shared decision-making supports better adherence to treatment.